97,662 Shares of 10x Genomics $TXG Bought by Fulcrum Asset Management LLP

Fulcrum Asset Management LLP purchased a new position in 10x Genomics (NASDAQ:TXG) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 97,662 shares of the company’s stock, valued at approximately $8,793,000. Fulcrum Asset Management LLP owned about 0.07% of 10x Genomics at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in TXG. Quantinno Capital Management LP increased its holdings in shares of 10x Genomics by 16.0% during the 1st quarter. Quantinno Capital Management LP now owns 5,411,761 shares of the company’s stock valued at $114,892,000 after acquiring an additional 744,558 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of 10x Genomics by 34.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,042,950 shares of the company’s stock valued at $43,357,000 after acquiring an additional 525,369 shares in the last quarter. Quantedge Capital Pte Ltd raised its stake in shares of 10x Genomics by 104.2% in the 1st quarter. Quantedge Capital Pte Ltd now owns 416,553 shares of the company’s stock valued at $8,843,000 after acquiring an additional 212,600 shares in the last quarter. Hsbc Holdings PLC acquired a new stake in 10x Genomics in the 1st quarter worth approximately $5,945,000. Finally, Swiss National Bank lifted its holdings in 10x Genomics by 2.2% in the 1st quarter. Swiss National Bank now owns 207,400 shares of the company’s stock worth $4,403,000 after purchasing an additional 4,400 shares during the last quarter. Institutional investors and hedge funds own 84.68% of the company’s stock.

Insider Activity

In other 10x Genomics news, Director John R. Stuelpnagel sold 20,000 shares of the firm’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $61.75, for a total value of $1,235,000.00. Following the sale, the director directly owned 328,436 shares in the company, valued at $20,280,923. This trade represents a 5.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Adam Taich sold 46,388 shares of the business’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $64.57, for a total transaction of $2,995,273.16. Following the transaction, the chief financial officer owned 316,344 shares in the company, valued at approximately $20,426,332.08. The trade was a 12.79% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 179,333 shares of company stock worth $11,810,070. Corporate insiders own 8.84% of the company’s stock.

Wall Street Analyst Weigh In

TXG has been the subject of a number of recent analyst reports. Leerink Partners upped their target price on 10x Genomics from $40.00 to $90.00 and gave the stock a “market perform” rating in a research report on Tuesday, September 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of 10x Genomics in a research report on Monday, September 21st. Piper Sandler boosted their price objective on shares of 10x Genomics from $47.00 to $80.00 and gave the stock a “neutral” rating in a research note on Monday, September 28th. Barclays boosted their price objective on shares of 10x Genomics from $52.00 to $110.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Finally, Argus initiated coverage on shares of 10x Genomics in a report on Monday, September 28th. They set a “buy” rating and a $110.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $68.07.

Key Stories Impacting 10x Genomics

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: 10x Genomics reported a Q3 loss of $0.15 per share, narrower than analysts’ expectations, while revenue of $150.7 million topped estimates. The company also raised its 2026 revenue outlook to $625 million–$635 million, above the roughly $620 million consensus. Q3 results
• Positive Sentiment: The company launched Sentira Single Cell, an AI-powered tool intended to simplify cell-data analysis. The product could support research adoption and create recurring revenue opportunities. Sentira launch
• Neutral Sentiment: Citigroup raised its price target from $50 to $60 but kept a neutral rating, suggesting limited upside at the cited share price. Citi target update
• Negative Sentiment: UBS cut its target from $90 to $61 and maintained a neutral rating. Meanwhile, Q3 revenue grew just 1.1% year over year and the company remains loss-making; management also cited production constraints and margin pressure, tempering optimism around stronger Atera demand. UBS target update Q3 call highlights

10x Genomics Price Performance

Shares of NASDAQ TXG opened at $59.28 on Monday. 10x Genomics has a 12 month low of $13.58 and a 12 month high of $102.81. The company has a market cap of $7.72 billion, a P/E ratio of -114.00 and a beta of 2.03. The business’s 50 day moving average is $73.95 and its two-hundred day moving average is $41.59.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.12. The company had revenue of $150.67 million during the quarter, compared to analysts’ expectations of $147.96 million. 10x Genomics had a negative return on equity of 8.26% and a negative net margin of 10.84%. 10x Genomics’s revenue for the quarter was up 1.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.22) earnings per share. Sell-side analysts expect that 10x Genomics will post -0.77 earnings per share for the current fiscal year.

About 10x Genomics

10x Genomics, Inc develops technology for studying biological systems at single-cell and spatial resolution. Its instruments, consumables and software help researchers analyze gene expression and other features of cells while preserving information about their location within tissue.

The company’s product platforms include Chromium for single-cell analysis, Visium for spatial gene-expression analysis and Xenium for in situ analysis of gene activity within tissue samples. Its tools are used in areas such as immunology, neuroscience, cancer research and drug discovery.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves research and clinical customers around the world, including academic institutions, biotechnology and pharmaceutical companies, and other research organizations.